Given a total testosterone of 33 ng/dL, hemoglobin A1c of 5.6 %, and DHEA‑S of 251 µg/dL, what is the appropriate next step in management?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Confirm the diagnosis with a repeat early morning fasting total testosterone, then initiate testosterone replacement therapy

With a total testosterone of 33 ng/dL—dramatically below the diagnostic threshold of 300 ng/dL—you should confirm this result with a second early morning fasting measurement and, assuming confirmation, proceed with testosterone replacement therapy after excluding contraindications. 1, 2

Diagnostic Confirmation Required

Both major guidelines mandate two separate early morning testosterone measurements before diagnosis 1, 2. Your patient's value of 33 ng/dL is profoundly low (normal range typically 300-1000 ng/dL), but a single measurement is insufficient. The second measurement should be:

  • Drawn between 7-11 AM, fasting
  • Using the same laboratory and assay method
  • Performed on a different day

The A1c of 5.6% is normal and doesn't alter management, though it's worth noting that diabetes and metabolic syndrome are associated with hypogonadism 1.

DHEA-S Interpretation

The DHEA-S of 251 µg/dL requires age-specific interpretation (normal ranges vary widely by age, typically 280-640 µg/dL for younger men, declining with age). This relatively low-normal to low value, combined with severely low testosterone, suggests:

  • Primary consideration: Evaluate for both primary and secondary hypogonadism
  • Measure LH, FSH, and prolactin to distinguish testicular failure (primary) from pituitary/hypothalamic dysfunction (secondary)
  • Consider morning cortisol to exclude adrenal insufficiency given the constellation of low androgens

While the DHEA-S/cortisol ratio has been studied as a biomarker for depressive symptoms in hypogonadism 3, this doesn't change your immediate management priority.

Pre-Treatment Evaluation

Before initiating testosterone therapy, you must exclude absolute contraindications 2:

Absolute contraindications:

  • Breast or prostate cancer
  • PSA >4 ng/mL (or >3 ng/mL in high-risk men without urological evaluation)
  • Hematocrit >48-50%
  • Myocardial infarction or stroke within 6 months
  • Uncontrolled heart failure
  • Severe untreated obstructive sleep apnea
  • Severe lower urinary tract symptoms
  • Thrombophilia

Required baseline assessments:

  • Digital rectal exam and PSA (if age >40 years)
  • Complete blood count (hematocrit)
  • Comprehensive metabolic panel
  • LH, FSH, prolactin
  • Consider: morning cortisol, iron studies, semen analysis if fertility desired

Treatment Approach

Transdermal testosterone is the preferred initial formulation 4, as it provides stable physiologic levels and allows easier dose titration. Target mid-normal testosterone range (450-600 ng/dL) 5.

Alternative formulations include:

  • Testosterone gel (daily application)
  • Intramuscular injections (less frequent but more variable levels)
  • Subcutaneous pellets
  • Nasal gel

Critical caveat: If fertility is a concern, testosterone therapy will suppress spermatogenesis. In such cases, gonadotropin therapy (hCG ± FSH) is required instead 4.

Monitoring Protocol

The monitoring schedule is standardized 2, 5:

At 3 months:

  • Total testosterone level (trough for injections, any time for transdermal)
  • Hematocrit
  • PSA (if age >40)
  • Symptom assessment

At 6 and 12 months:

  • Repeat above parameters

Annually thereafter:

  • Continue monitoring testosterone, hematocrit, PSA
  • Assess for symptom improvement and adverse effects

Hematocrit management: If hematocrit rises above 54%, temporarily discontinue therapy and consider phlebotomy 6. Upon resumption, consider switching to transdermal formulations which cause less erythrocytosis than injections.

Expected Outcomes

Symptom improvement typically begins at 3-6 weeks but may take 3-6 months for full effect 7. Testosterone therapy reliably improves:

  • Sexual function and libido
  • Energy and mood
  • Muscle mass and strength
  • Bone mineral density
  • Body composition (decreased fat mass)

Recent evidence confirms no increased risk of major cardiovascular events or prostate cancer with appropriate monitoring 5.

Common Pitfalls to Avoid

  1. Don't start therapy without confirming the diagnosis with a second morning testosterone
  2. Don't forget to check LH/FSH to determine primary vs. secondary hypogonadism—this affects fertility counseling and may reveal pituitary pathology
  3. Don't overlook contraindications, particularly occult prostate cancer in men >40
  4. Don't use testosterone if fertility is desired—refer for gonadotropin therapy instead
  5. Don't fail to monitor hematocrit—polycythemia is the most common serious adverse effect requiring intervention

Given the profoundly low testosterone level of 33 ng/dL, this patient almost certainly has true hypogonadism requiring treatment, but proper diagnostic confirmation and pre-treatment evaluation are mandatory before proceeding.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.